Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy Johnson BA 3rd; Baban B; Mellor ALImmunotherapy 2009[Jul]; 1 (4): 645-61Natural immune tolerance is a formidable barrier to successful immunotherapy to treat established cancers and chronic infections. Conversely, creating robust immune tolerance via immunotherapy is the major goal in treating autoimmune and allergic diseases, and enhancing survival of transplanted organs and tissues. In this review, we focus on a natural mechanism that creates local T-cell tolerance in many clinically relevant settings of chronic inflammation involving expression of the cytosolic enzyme indoleamine 2,3-dioxygenase (IDO) by specialized subsets of dendritic cells. IDO-expressing dendritic cells suppress antigen-specific T-cell responses directly, and induce bystander suppression by activating regulatory T cells. Thus, manipulating IDO is a promising strategy to treat a range of chronic inflammatory diseases.|*Immunotherapy[MESH]|Animals[MESH]|Autoimmune Diseases/*immunology/therapy[MESH]|Bystander Effect[MESH]|Dendritic Cells/immunology/metabolism/pathology[MESH]|Graft Rejection/*immunology/therapy[MESH]|Humans[MESH]|Hypersensitivity/*immunology/therapy[MESH]|Immunosuppression Therapy[MESH]|Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics/immunology/*metabolism[MESH]|Inflammation[MESH]|T-Lymphocytes, Regulatory/*immunology[MESH] |
